Effect of Granisetron on Anticipatory Nausea and Vomiting in Chemotherapy Patients
Author Information
Author(s): M.S. Aapro, V. Kirchner, J.P. Terrey
Primary Institution: Centre Anticancereux, Switzerland
Hypothesis
Does the use of granisetron reduce the incidence of anticipatory nausea and vomiting in patients undergoing repeat cycle chemotherapy?
Conclusion
Granisetron may lead to a lower incidence of anticipatory nausea and vomiting in patients receiving repeat cycles of chemotherapy.
Supporting Evidence
- Less than 10% of patients displayed symptoms of anticipatory nausea.
- 2% or less had symptoms of anticipatory vomiting.
- A consistent complete response rate over 59% was seen in this cohort of patients.
Takeaway
This study found that giving a medicine called granisetron helps people feel less sick before they get their chemotherapy again.
Methodology
Patients received granisetron before chemotherapy and were monitored for symptoms of anticipatory nausea and vomiting.
Potential Biases
Selection bias may have occurred as poorly responding patients were often switched to alternative treatments.
Limitations
The study was retrospective and lacked a control group, which may introduce bias.
Participant Demographics
The study included 574 chemotherapy patients, with a higher proportion of females experiencing anticipatory nausea and vomiting.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website